Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-02-26 @ 8:41 AM
Study NCT ID:
NCT05036434
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2025-08-01
First Post:
2021-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
Sponsor:
National Cancer Center, Korea
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-11-15
Start Date Type:
ACTUAL
Primary Completion Date:
2025-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-26
First Submit QC Date:
None
Study First Post Date:
2021-09-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-29
Last Update Post Date:
2025-08-01
Last Update Post Date Type:
ACTUAL